Cargando…
Use of MIRUS™ for MAC-driven application of isoflurane, sevoflurane, and desflurane in postoperative ICU patients: a randomized controlled trial
BACKGROUND: The MIRUS™ (TIM, Koblenz, Germany) is an electronical gas delivery system, which offers an automated MAC (minimal alveolar concentration)-driven application of isoflurane, sevoflurane, or desflurane, and can be used for sedation in the intensive care unit. We investigated its consumption...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6795651/ https://www.ncbi.nlm.nih.gov/pubmed/31620921 http://dx.doi.org/10.1186/s13613-019-0594-8 |
_version_ | 1783459486061559808 |
---|---|
author | Bellgardt, Martin Georgevici, Adrian Iustin Klutzny, Mitja Drees, Dominik Meiser, Andreas Gude, Philipp Vogelsang, Heike Weber, Thomas Peter Herzog-Niescery, Jennifer |
author_facet | Bellgardt, Martin Georgevici, Adrian Iustin Klutzny, Mitja Drees, Dominik Meiser, Andreas Gude, Philipp Vogelsang, Heike Weber, Thomas Peter Herzog-Niescery, Jennifer |
author_sort | Bellgardt, Martin |
collection | PubMed |
description | BACKGROUND: The MIRUS™ (TIM, Koblenz, Germany) is an electronical gas delivery system, which offers an automated MAC (minimal alveolar concentration)-driven application of isoflurane, sevoflurane, or desflurane, and can be used for sedation in the intensive care unit. We investigated its consumption of volatile anesthetics at 0.5 MAC (primary endpoint) and the corresponding costs. Secondary endpoints were the technical feasibility to reach and control the MAC automatically, the depth of sedation at 0.5 MAC, and awakening times. Mechanically ventilated and sedated patients after major surgery were enrolled. Upon arrival in the intensive care unit, patients obtained intravenous propofol sedation for at least 1 h to collect ventilation and blood gas parameters, before they were switched to inhalational sedation using MIRUS™ with isoflurane, sevoflurane, or desflurane. After a minimum of 2 h, inhalational sedation was stopped, and awakening times were recorded. A multivariate electroencephalogram and the Richmond Agitation Sedation Scale (RASS) were used to assess the depth of sedation. Vital signs, ventilation parameters, gas consumption, MAC, and expiratory gas concentrations were continuously recorded. RESULTS: Thirty patients obtained inhalational sedation for 18:08 [14:46–21:34] [median 1st–3rd quartiles] hours. The MAC was 0.58 [0.50–0.64], resulting in a Narcotrend Index of 37.1 [30.9–42.4] and a RASS of − 3.0 [− 4.0 to (− 3.0)]. The median gas consumption was significantly lowest for isoflurane ([ml h(−1)]: isoflurane: 3.97 [3.61–5.70]; sevoflurane: 8.91 [6.32–13.76]; and desflurane: 25.88 [20.38–30.82]; p < 0.001). This corresponds to average costs of 0.39 € h(−1) for isoflurane, 2.14 € h(−1) for sevoflurane, and 7.54 € h(−1) for desflurane. Awakening times (eye opening [min]: isoflurane: 9:48 [4:15–20:18]; sevoflurane: 3:45 [0:30–6:30]; desflurane: 2:00 [1:00–6:30]; p = 0.043) and time to extubation ([min]: isoflurane: 10:10 [8:00–20:30]; sevoflurane: 7:30 [4:37–14:22]; desflurane: 3:00 [3:00–6:00]; p = 0.007) were significantly shortest for desflurane. CONCLUSIONS: A target-controlled, MAC-driven automated application of volatile anesthetics is technically feasible and enables an adequate depth of sedation. Gas consumption was highest for desflurane, which is also the most expensive volatile anesthetic. Although awakening times were shortest, the actual time saving of a few minutes might be negligible for most patients in the intensive care unit. Thus, using desflurane seems not rational from an economic perspective. Trial registration Clinical Trials Registry (ref.: NCT03860129). Registered 24 September 2018—Retrospectively registered. |
format | Online Article Text |
id | pubmed-6795651 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-67956512019-10-24 Use of MIRUS™ for MAC-driven application of isoflurane, sevoflurane, and desflurane in postoperative ICU patients: a randomized controlled trial Bellgardt, Martin Georgevici, Adrian Iustin Klutzny, Mitja Drees, Dominik Meiser, Andreas Gude, Philipp Vogelsang, Heike Weber, Thomas Peter Herzog-Niescery, Jennifer Ann Intensive Care Research BACKGROUND: The MIRUS™ (TIM, Koblenz, Germany) is an electronical gas delivery system, which offers an automated MAC (minimal alveolar concentration)-driven application of isoflurane, sevoflurane, or desflurane, and can be used for sedation in the intensive care unit. We investigated its consumption of volatile anesthetics at 0.5 MAC (primary endpoint) and the corresponding costs. Secondary endpoints were the technical feasibility to reach and control the MAC automatically, the depth of sedation at 0.5 MAC, and awakening times. Mechanically ventilated and sedated patients after major surgery were enrolled. Upon arrival in the intensive care unit, patients obtained intravenous propofol sedation for at least 1 h to collect ventilation and blood gas parameters, before they were switched to inhalational sedation using MIRUS™ with isoflurane, sevoflurane, or desflurane. After a minimum of 2 h, inhalational sedation was stopped, and awakening times were recorded. A multivariate electroencephalogram and the Richmond Agitation Sedation Scale (RASS) were used to assess the depth of sedation. Vital signs, ventilation parameters, gas consumption, MAC, and expiratory gas concentrations were continuously recorded. RESULTS: Thirty patients obtained inhalational sedation for 18:08 [14:46–21:34] [median 1st–3rd quartiles] hours. The MAC was 0.58 [0.50–0.64], resulting in a Narcotrend Index of 37.1 [30.9–42.4] and a RASS of − 3.0 [− 4.0 to (− 3.0)]. The median gas consumption was significantly lowest for isoflurane ([ml h(−1)]: isoflurane: 3.97 [3.61–5.70]; sevoflurane: 8.91 [6.32–13.76]; and desflurane: 25.88 [20.38–30.82]; p < 0.001). This corresponds to average costs of 0.39 € h(−1) for isoflurane, 2.14 € h(−1) for sevoflurane, and 7.54 € h(−1) for desflurane. Awakening times (eye opening [min]: isoflurane: 9:48 [4:15–20:18]; sevoflurane: 3:45 [0:30–6:30]; desflurane: 2:00 [1:00–6:30]; p = 0.043) and time to extubation ([min]: isoflurane: 10:10 [8:00–20:30]; sevoflurane: 7:30 [4:37–14:22]; desflurane: 3:00 [3:00–6:00]; p = 0.007) were significantly shortest for desflurane. CONCLUSIONS: A target-controlled, MAC-driven automated application of volatile anesthetics is technically feasible and enables an adequate depth of sedation. Gas consumption was highest for desflurane, which is also the most expensive volatile anesthetic. Although awakening times were shortest, the actual time saving of a few minutes might be negligible for most patients in the intensive care unit. Thus, using desflurane seems not rational from an economic perspective. Trial registration Clinical Trials Registry (ref.: NCT03860129). Registered 24 September 2018—Retrospectively registered. Springer International Publishing 2019-10-16 /pmc/articles/PMC6795651/ /pubmed/31620921 http://dx.doi.org/10.1186/s13613-019-0594-8 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Research Bellgardt, Martin Georgevici, Adrian Iustin Klutzny, Mitja Drees, Dominik Meiser, Andreas Gude, Philipp Vogelsang, Heike Weber, Thomas Peter Herzog-Niescery, Jennifer Use of MIRUS™ for MAC-driven application of isoflurane, sevoflurane, and desflurane in postoperative ICU patients: a randomized controlled trial |
title | Use of MIRUS™ for MAC-driven application of isoflurane, sevoflurane, and desflurane in postoperative ICU patients: a randomized controlled trial |
title_full | Use of MIRUS™ for MAC-driven application of isoflurane, sevoflurane, and desflurane in postoperative ICU patients: a randomized controlled trial |
title_fullStr | Use of MIRUS™ for MAC-driven application of isoflurane, sevoflurane, and desflurane in postoperative ICU patients: a randomized controlled trial |
title_full_unstemmed | Use of MIRUS™ for MAC-driven application of isoflurane, sevoflurane, and desflurane in postoperative ICU patients: a randomized controlled trial |
title_short | Use of MIRUS™ for MAC-driven application of isoflurane, sevoflurane, and desflurane in postoperative ICU patients: a randomized controlled trial |
title_sort | use of mirus™ for mac-driven application of isoflurane, sevoflurane, and desflurane in postoperative icu patients: a randomized controlled trial |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6795651/ https://www.ncbi.nlm.nih.gov/pubmed/31620921 http://dx.doi.org/10.1186/s13613-019-0594-8 |
work_keys_str_mv | AT bellgardtmartin useofmirusformacdrivenapplicationofisofluranesevofluraneanddesfluraneinpostoperativeicupatientsarandomizedcontrolledtrial AT georgeviciadrianiustin useofmirusformacdrivenapplicationofisofluranesevofluraneanddesfluraneinpostoperativeicupatientsarandomizedcontrolledtrial AT klutznymitja useofmirusformacdrivenapplicationofisofluranesevofluraneanddesfluraneinpostoperativeicupatientsarandomizedcontrolledtrial AT dreesdominik useofmirusformacdrivenapplicationofisofluranesevofluraneanddesfluraneinpostoperativeicupatientsarandomizedcontrolledtrial AT meiserandreas useofmirusformacdrivenapplicationofisofluranesevofluraneanddesfluraneinpostoperativeicupatientsarandomizedcontrolledtrial AT gudephilipp useofmirusformacdrivenapplicationofisofluranesevofluraneanddesfluraneinpostoperativeicupatientsarandomizedcontrolledtrial AT vogelsangheike useofmirusformacdrivenapplicationofisofluranesevofluraneanddesfluraneinpostoperativeicupatientsarandomizedcontrolledtrial AT weberthomaspeter useofmirusformacdrivenapplicationofisofluranesevofluraneanddesfluraneinpostoperativeicupatientsarandomizedcontrolledtrial AT herzogniesceryjennifer useofmirusformacdrivenapplicationofisofluranesevofluraneanddesfluraneinpostoperativeicupatientsarandomizedcontrolledtrial |